Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
China Resources Pharmaceutical Group (STU:640) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
China Resources Pharmaceutical Group's EV-to-EBIT for today is
China Resources Pharmaceutical Group's current Enterprise Value is €16,956 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €1,672 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
China Resources Pharmaceutical Group's EV-to-EBITDA for today is:
China Resources Pharmaceutical Group's current Enterprise Value is €16,956 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €2,166 Mil.
China Resources Pharmaceutical Group's current Enterprise Value is €16,956 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €32,620 Mil.
China Resources Pharmaceutical Group's current Enterprise Value is €16,956 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €2,482 Mil.
China Resources Pharmaceutical Group's current Enterprise Value is €16,956 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €2,053 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group Enterprise Value Related Terms
China Resources Pharmaceutical Group Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group Enterprise Value Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's Enterprise Value falls into.
China Resources Pharmaceutical Group Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group (STU:640) has a Enterprise Value of €16,956 Mil as of Jul. 04, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on China Resources Pharmaceutical Group and its competitors.
Is China Resources Pharmaceutical Group's Enterprise Value too high?
China Resources Pharmaceutical Group's current Enterprise Value is €16,956 Mil. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Enterprise Value compare to ZTS and UTHR?
China Resources Pharmaceutical Group's Enterprise Value of €16,956 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on China Resources Pharmaceutical Group and its competitors. China Resources Pharmaceutical Group's current Enterprise Value is €16,956 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.64, compared to a current price of €0.49 — trading 24.1% below its estimated fair value. The current Enterprise Value is €16,956 Mil. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current Enterprise Value is €16,956 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.49 is trading 24.1% below its estimated GF Value™ of €0.64.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
Enterprise Value: €16,956 Mil
GF Value™: €0.64 vs. price of €0.49 (24.1% below fair value)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score
Get the complete analysis for STU:640
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
